Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates

Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza · 2023

Read Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates by Patricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10754519.txt.

Description

Patricia Pérez and co-authors test in 2023 vaccine candidates against the beta variant of the virus that causes COVID-19. The vaccines use a harmless poxvirus shell to carry the variant's spike protein, tuned to hold its shape. Constant new variants keep forcing vaccine updates, so a fast platform matters.

Two shots fully protected gene-edited mice from a lethal beta challenge, clearing virus from lungs and easing lung damage. Antibodies rose against the original virus and five variants, and immune cells responded after a single nose dose. The results support taking these candidates toward human trials as variant-ready options.

Catalog record

CREATORPatricia Pérez, Guillermo Albericio, David Astorgano, Sara Flores, Cristina Sánchez-Corzo, Pedro J. Sánchez-Cordón, Joanna Luczkowiak, Rafael Delgado, José M. Casasnovas, Mariano Esteban, Juan García-Arriaza
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10754519

Browse the full library · About the Tower of Babel